Skip to main content
. 2021 Oct 25;54(11-12):1432–1441. doi: 10.1111/apt.16663

TABLE 1.

Baseline characteristics of IBD patients with SARS‐CoV‐2 infection

IBD (n = 937) UC (n = 446) CD (n = 491) P value
Age, years, median (range) 44 (10‐86) 47 (10‐86) 43 (12‐84) <0.001
Age ≥60 years, n (%) 185 (19.7) 106 (23.7) 75 (15.2) 0.003
Males, n (%) 513 (54.7) 252 (56.5) 261 (53.1) 0.43
Current smokers, n (%) 148 (15.8) 59 (13.2) 89 (18.1) 0.05
Disease duration, years, median (range) 11 (0‐71) 11 (0‐61) 11 (0‐71) 1.00
Disease activity, n (%)
Remission 559 (59.6) 254 (56.9) 305 (62.1) 0.002
Mild 211 (22.5) 99 (22.1) 112 (22.8) 0.002
Moderate 124 (13.2) 63 (14.1) 61 (12.4) 0.89
Severe 41 (4.3) 20 (4.4) 21 (4.2) 1.00
Therapy, n (%) a
None 56 (6.0) 20 (4.4) 36 (7.3) 0.11
Salicylates 492 (52.5) 333 (74.6) 159 (32.3) <0.001
Corticosteroids 122 (13.0) 70 (15.6) 52 (10.5) 0.04
Immunomodulators 101 (11.2) 47 (10.5) 54 (10.9) 0.75
TNF antagonists 346 (36.9) 114 (25.5) 232 (47.2) <0.001
TNF antagonists + immunomodulators 22 (2.3) 9 (2.0) 13 (2.6) 0.61
Vedolizumab 115 (12.3) 71 (15.9) 44 (8.9) <0.001
Ustekinumab 51 (5.4) 4 (0.9) 47 (9.5) <0.001
Other 13 (1.4) 8 (1.7) 5 (1.0) 0.50
Comorbidities, n (%) 376 (40.1) 188 (42.1) 188 (38.2) 0.32
IMID 116 (12.4) 47 (10.5) 69 (14.1) 0.11
Arterial hypertension b 89 (9.5) 55 (12.3) 34 (6.9) 0.01
Obesity c 21 (2.2) 12 (2.6) 9 (1.8) 0.55
Charlson's comorbidity index, n (%)
0 538 (57.4) 234 (52.5) 311 (63.3) <0.001
1 178 (20.7) 96 (21.5) 84 (17.1) 0.34
2 102 (21.9) 57 (12.8) 68 (13.8) 0.08
3 59 (6.2) 32 (7.2) 27 (5.4) 0.06
4 18 (1.9) 9 (2.0) 9 (1.8) 0.05
5 15 (1.6) 10 (2.2) 5 (1.0) 0.25
6 9 (0.9) 6 (1.3) 3 (0.6) 0.21
7 1 (0.1) 1 (0.2) 0 (0) 1.00
8 1 (0.1) 1 (0.2) 0 (0) 1.00

Abbreviations: CD, Crohn's disease; IMID, immune‐mediated inflammatory disease; UC, ulcerative colitis.

a

The data reflect the fact that some patients were taking more than one therapy simultaneously.

b

Defined as >140/90 mm Hg.

c

Body mass index >30 kg/m2.